title: Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
abstract: In this study, we investigated the clinical effects of long-term administration of the phosphorus (P) binder lanthanum carbonate (LC), which was launched in Japan in 2009. The subjects were 58 dialysis patients who began receiving LC, and we evaluated the clinical effects for up to 36 months after treatment initiation. The average serum P concentration remained low during the 36-month study period, with a significant reduction from 6.25 mg/dL at the start of the study to 4.94 mg/dL after 36 months (P < 0.001). A significant reduction was also observed in the average serum calcium concentration after 36 months (P < 0.05), but not in the serum intact parathyroid hormone concentration. Significant reductions were also observed in the average serum total protein, albumin and potassium concentrations (P < 0.05). The dosages of LC increased by approximately 1.9-fold after 36 months, in contrast, the dosages of concomitantly used sevelamer hydrochloride and Ca carbonate preparations decreased. These results indicate that LC could be used to treat hyperphosphatemia without causing hypercalcemia, and would be useful for long-term treatment with hemodialysis patients.
authors: Department of Nephrology, Sakura Memorial Hospital, Saitama, Japan.
authors: Yuichiro
authors: Y
authors: Kishi
authors: Yoshihiro
authors: Y
authors: Obara
authors: Keiko
authors: K
authors: Hara
authors: Hiromitsu
authors: H
authors: Yamashiro
authors: Norio
authors: N
authors: Kurosawa
authors: Daisuke
authors: D
authors: Takada
mesh_terms: D000368:Aged; D002118:Calcium / Q000097:blood*; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007564:Japan; D007676:Kidney Failure, Chronic / Q000628:therapy; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis / Q000379:methods*; D000069603:Sevelamer; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002614:Chelating Agents; D010281:Parathyroid Hormone; D011073:Polyamines; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium
keywords: laboratory parameters; lanthanum carbonate; long-term effects; serum phosphorus concentrations